Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175
- PMID: 25998309
- DOI: 10.2337/dc15-0519
Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175
Comment on
-
Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!Diabetes Care. 2015 Jan;38(1):170-5. doi: 10.2337/dc14-0565. Diabetes Care. 2015. PMID: 25538314
-
Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.Diabetes Care. 2015 Jun;38(6):e94. doi: 10.2337/dc15-0293. Diabetes Care. 2015. PMID: 25998308 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical